March 9th, 2013
ACC.13 Headquarters
CardioExchange Editors, Staff
CardioExchange is dedicated to bringing you the latest from ACC.13. Check out our coverage below ─ and some of the great debates these posts have sparked ─ then tell us what you think!
News:
- Following an Embargo Break PREVAIL Trial Won’t be Presented at ACC
- HPS2-THRIVE: A ‘Disappointing But Clear’ Result
- Cangrelor During PCI May Reduce Ischemic Events
- Fibrinolysis May Benefit Late-Arriving STEMI Patients
- Eplerenone May Prevent Heart Failure in Acute STEMI Patients
- Another Negative Trial of Darbepoetin Alfa
- Was Atherosclerosis the Real Curse of the Mummy?
- Two Trials Explore On-Pump Versus Off-Pump Bypass Surgery
Analysis:
Follow our Fellows:
- The Real World Intrudes on the Start of the Meeting
- A Fellow Reflects on the Program and on her Progress from Observer to Educator
- Data Sources for Young Investigators
- New Approaches to LDL Lowering
- Great Venue, Great Sessions, but Disappointments Too
- Thinking About What Comes After Fellowship
- The Real Question About Reducing Hospital Readmissions
- You Are My Sunshine
- Learning to Network
NEJM — Recent Cardiology Articles- Utah’s Prescription-Renewal Pilot Program — Autonomous AI Managing Patient Care April 23, 2026Utah recently rolled out a pilot program involving an AI system that autonomously renews certain prescriptions for people with chronic conditions. This program raises important clinical and legal issues.
- Double Take: HFpEF Explained — Prevalence, New Advances, and How to Diagnose April 23, 2026This Double Take video reviews heart failure with preserved ejection fraction, its risk factors and causes, and the challenge in establishing the diagnosis.
- Blood-Pressure Control after Intracerebral Hemorrhage — An Unbroken Glass Ceiling April 23, 2026Effective blood-pressure control is the cornerstone of management after intracerebral hemorrhage; it is both the primary determinant of risk and the most vital intervention for reducing the threat of a second vascular event.1 Yet, despite the availability of effective treatments, blood pressure remains poorly controlled in survivors of...
- Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage April 23, 2026Among survivors of intracerebral hemorrhage, a single pill with three low-dose antihypertensive agents added to standard care was associated with a lower incidence of stroke and major cardiovascular events than placebo.
- Glucocorticoids in Kawasaki Disease — Refining Indications and the Science April 16, 2026Kawasaki disease is the most common cause of acquired heart disease in children in the developed world.1 Although Kawasaki disease manifests with acute, transient systemic signs, its long-term morbidity derives from necrotizing vasculitis that predominantly affects the coronary arteries.2,3 The primary goal of therapy during the...
- Utah’s Prescription-Renewal Pilot Program — Autonomous AI Managing Patient Care April 23, 2026